XTL Biopharmaceuticals Ltd.

Legal Proceedings Report • Nov 16, 2005

C004	��� �� �� ������������� ��"�		2
Public	X T L BIOPHARMACEUTICALS LTD
	4312	Corporation no: 520039470
	Stock Exchange/Market: ��� �� ��
	1996
	352	Hasapir 3 , Nes Ziona 76100 , ,
	Tel: 08-9304444 , Fax: 08-9304445
	E.mail address: rcohen@xtlbio.com	Date of transmission: 16/11/2005
		Time of broadcast: 09:52 09:51:56
		Reference: 2005-02-088204

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate report on other matterDon't use this form if there is more adequate one

XTLbio announces data demonstrating the antiviral activity of one of the two antibodies comprising XTLbio�s lead Hepatitis C drug candidate - XTL6865
Attached file 23-05XTLbio_AASLD16Nov05_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 06/11/2005
- - -
Name of the Signatory : Burgin Jonathan , , Position of Signatory in the reporting corporation: Chief Financial Officer
Hasapir Telephone: 08-9304440 , Facsimile: 08-9300659 , E-mail: jburgin@xtlbio.com